Radiopharm Theranostics Limited (RADX)

Radiopharm Theranostics Cash Flow Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Net Income	-43	-47.95	-34.61	-30.42	-1.16
Depreciation & Amortization	4.64	3.13	3.3	2.98	-
Loss (Gain) From Sale of Assets	1.69	1.69	-	-	-
Asset Writedown & Restructuring Costs	1.48	1.48	3.1	-	-
Stock-Based Compensation	2.64	2.64	3.04	4.8	0.86
Other Operating Activities	-7.92	8.99	3.81	10.48	0
Change in Accounts Receivable	3.48	3.48	-4.28	-0.05	-0.02
Change in Accounts Payable	3.5	3.5	2.35	2.53	0.24
Change in Other Net Operating Assets	0.07	0.07	0.1	-0.23	-
Operating Cash Flow	-33.42	-22.98	-23.2	-9.91	-0.08
Capital Expenditures	-	-	-0.05	-0	-
Sale (Purchase) of Intangibles	3	-	-1.49	-28.34	-
Investment in Securities	-	-	-	-0.04	-
Investing Cash Flow	3	-	-1.53	-28.38	-
Short-Term Debt Issued	-	-	-	0.01	-
Long-Term Debt Issued	-	7.37	-	-	-
Total Debt Issued	4.4	7.37	-	0.01	0.14
Short-Term Debt Repaid	-	-	-	-0.07	-
Long-Term Debt Repaid	-	-5.17	-	-	-
Total Debt Repaid	-4.1	-5.17	-	-0.07	-
Net Debt Issued (Repaid)	0.3	2.2	-	-0.06	0.14
Issuance of Common Stock	73.37	29.65	10.07	70	0
Other Financing Activities	-9.17	-1.97	-0.85	-4.83	-
Financing Cash Flow	64.51	29.88	9.22	65.11	0.14
Foreign Exchange Rate Adjustments	0.46	-0.03	0.23	0.13	-
Net Cash Flow	34.54	6.88	-15.28	26.95	0.07
Free Cash Flow	-33.42	-22.98	-23.25	-9.91	-0.08
Free Cash Flow Margin	-10107.88%	-1173.12%	-374.36%	-	-
Free Cash Flow Per Share	-0.03	-0.06	-0.08	-0.06	-
Cash Income Tax Paid	0	-4.85	-1.56	-	-
Levered Free Cash Flow	-16.48	-12.04	-12.08	-31.35	-
Unlevered Free Cash Flow	-16.1	-11.64	-12.03	-25.51	-
Change in Working Capital	7.05	7.05	-1.84	2.25	0.22

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q